Nuwellis Continues Clinician-Driven Growth in Pediatric Care with a Leading Hospital in the Northeast U.S.
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) announced that a leading children’s hospital in the Northeast U.S. has initiated an Aquadex Ultrafiltration Program on Dec. 4, 2025. Pediatric nephrology and cardiology teams are adopting Aquadex for its minimal extracorporeal volume and real-time hematocrit monitoring to manage fluid-sensitive, high-acuity pediatric patients.
The company says Aquadex usage is expanding across leading children’s hospitals nationwide and is being integrated into care pathways for complex cardiac, cardio-renal, and critical care cases, supporting Nuwellis’ pediatric growth strategy.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NUWE gained 9.83%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.6% during that session. Argus tracked a trough of -3.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $392K to the company's valuation, bringing the market cap to $4M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
NUWE gained 6.17% while key peers were mostly lower: BBLG -6.26%, VTAK -7.08%, VERO -0.54%, NAOV -1.95%, with only TIVC +14.16% higher, suggesting a stock-specific move rather than a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Clinical data update | Positive | -1.3% | Lenox Hill real-world Aquadex data across 69 critical-care cases. |
| Dec 04 | Pediatric adoption news | Positive | +9.8% | Leading Northeastern children’s hospital initiated Aquadex program. |
| Nov 12 | Quarterly earnings | Negative | -4.0% | Q3 2025 revenue decline YoY and operating loss despite sequential growth. |
| Nov 10 | Patent allowance | Positive | -5.6% | Notice of allowance for advanced clamp safety tech for Vivian system. |
| Oct 23 | Earnings notice | Neutral | -3.5% | Announcement of Q3 2025 results date and conference call details. |
Recent history shows mixed alignment: positive clinical and IP news often saw negative price reactions, while the latest pediatric adoption and the November earnings release aligned with price moves.
Over the last few months, Nuwellis reported several milestones, including Q3 2025 results with $2.2 million revenue and a 65.2% gross margin, alongside an operating loss of $2.7 million and $3.1 million in cash. The company highlighted expanding Aquadex use in critical care and pediatric settings and received a U.S. patent notice of allowance for the Vivian™ pediatric system. A Lenox Hill Hospital study presented at ASN Kidney Week reviewed 69 Aquadex cases, reinforcing broader clinical utility. Today’s pediatric-focused announcement fits this ongoing shift toward high-acuity pediatric applications.
Market Pulse Summary
The stock moved +9.8% in the session following this news. A strong positive reaction aligns with the article’s emphasis on clinician-driven growth in high-acuity pediatric care, reinforcing Aquadex as a strategic pillar. However, past patterns show several positive clinical and IP updates were followed by negative moves, and filings highlight ongoing losses and capital raises, including an at-the-market program for up to $4,650,000. Investors had to weigh this pediatric momentum against financing needs and prior volatility around news events.
Key Terms
ultrafiltration medical
extracorporeal medical
hematocrit medical
cardio-renal medical
AI-generated analysis. Not financial advice.
Pediatric nephrology and cardiology teams continue to seek out Aquadex for safe, precise fluid management in complex cases
MINNEAPOLIS, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, announced today that a leading Northeastern U.S. children’s hospital has initiated an Aquadex Ultrafiltration Program. Pediatric nephrology and cardiology teams across the country continue to seek out the therapy for its minimal extracorporeal volume requirement and reliability in managing fluid-sensitive patients, driving steady growth in Nuwellis’ expanding pediatric market.
Aquadex adoption continues to accelerate in high-acuity pediatric settings nationwide. Children’s hospitals are integrating the therapy into care pathways for complex cardiac, cardio-renal, and critical care cases as teams look for controlled, predictable approaches to fluid management. This broader institutional uptake highlights both the clinical value physicians see in Aquadex and the strategic importance of the pediatric market within Nuwellis’ long-term growth plan.
“Our growth in pediatrics is being led by the clinicians themselves,” said John Erb, CEO of Nuwellis. “Pediatric nephrology and cardiology teams are seeking out Aquadex because it gives them a level of control and safety they haven’t had with traditional approaches. Their adoption of the therapy is also creating a meaningful and expanding pillar of growth for our business.”
With the addition of this new key customer, Aquadex is now utilized across a growing number of leading children’s hospitals nationwide. The consistent expansion across regions and specialties demonstrates how Aquadex is becoming a trusted solution in modern pediatric fluid-management strategies.
“Pediatric clinicians come to Nuwellis seeking a reliable solution for precise fluid volume management,” said Kelsey Newell, Senior Director, Medical Affairs. “The real-time hematocrit monitoring built into Aquadex allows teams to directly assess patient tolerance during fluid removal, which is essential in critical care. That level of visibility is what makes Aquadex stand apart in supporting fragile pediatric disease states.”
Nuwellis remains committed to supporting pediatric specialists and hospital systems as Aquadex becomes more widely used in complex care environments across the country.
For more information, visit www.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
FAQ
What did Nuwellis (NUWE) announce on December 4, 2025 about pediatric care?
Why are pediatric teams choosing Aquadex according to Nuwellis (NUWE)?
How is Aquadex being used in children’s hospitals as of Dec. 4, 2025?
Does the announcement say Aquadex adoption is regional or national for NUWE?
What clinical feature does Nuwellis highlight as important for pediatric critical care?
Where can investors find more information about Nuwellis and Aquadex?
